Stendra exists. Almost no U.S. telehealth platform prescribes it. Here's the trade.

Ask 100 men with an ED prescription what they're taking. ~95 say sildenafil or tadalafil. Maybe 4 say vardenafil. One says avanafil — and he's lying or in a clinical trial.

Avanafil (brand name Stendra in the U.S., Spedra in the EU) hits in 15 minutes. It's the most selective of the four PDE5 inhibitors — meaning fewer blue-vision episodes and fewer next-day muscle aches. It is, on paper, the cleanest molecule in the class.

So why doesn't anyone get it? Three reasons, none of them clinical.

The 15-minute number is the real one.

Open the FDA Stendra label (NDA 202-276). Onset section reads: "as early as 15 minutes." That's not marketing. That's the lower bound of the company's own pharmacokinetic data, which the FDA signed off on.

In the pivotal trial (Goldstein et al., J Sex Med 2012, PMID 22248153), 100mg avanafil produced a measurable erectile response at the 15-minute timepoint in roughly a third of subjects, climbing to ~80% by 30 minutes. Compare to sildenafil's labeled 30-60 minute window and tadalafil's 30 minute - 2 hour band.

Half-life is around 5 hours. That's not the long tail of tadalafil's 17.5 hours, and it's comparable to sildenafil's ~4-hour terminal half-life (FDA Viagra label). Avanafil's window is the same shape as sildenafil's, just shifted forward by 30-45 minutes on the front end.

Practically: take it during dinner, not before dinner. The rest of the PDE5 class wants you to plan an hour ahead. Avanafil lets you decide closer to the moment.

That's the entire pitch. Whether it matters to you depends on whether you live a planned sex life or a "this is happening now, where are my pills" life.

Cost-wise: brand $50-65/pill, generic $7-10 cash, personal-import $4-6/pill.

PDE6 and PDE11 — the selectivity case.

Sildenafil hits PDE5. It also nudges PDE6 (in the retina — the source of the "blue tinge" or chromatopsia some men report) and barely touches PDE11. Tadalafil is the opposite: it ignores PDE6 (almost zero visual side effects) but hits PDE11 in skeletal muscle (which is why some men get back pain or muscle aches the next day).

Think of PDE5 as the lock you want to open. PDE6 is the lock in your retina; PDE11 is the lock in your back muscles. Sildenafil sometimes opens PDE6 by accident (blue tinge). Tadalafil sometimes opens PDE11 by accident (back pain). Avanafil basically only touches PDE5.

Avanafil's selectivity numbers (Wang et al., J Sex Med 2012; ICOS in vitro data, Mehrotra et al., Eur Urol 2012) sit at roughly 120-fold selectivity for PDE5 over PDE6, and over 10,000-fold for PDE5 over PDE11.

Translation: it doesn't trigger blue-tinge vision the way sildenafil sometimes does, and it doesn't trigger the next-day muscle ache the way tadalafil sometimes does. In Belkoff LH, McCullough A, Goldstein I, Hellstrom WJ et al. (Int J Clin Pract 2013, PMID 23521325, long-term safety study), chromatopsia was reported in well under 1% of avanafil patients across multiple studies. Sildenafil's labeled rate is 3-11% depending on dose (per Viagra prescribing information).

The clinical relevance: small. Most men on sildenafil never notice the blue tinge, and most on tadalafil never get back pain. But if you're one of the men who does notice — particularly if you work on screens all day, or you lift weights and don't want to be guessing whether your back is sore from squats or from Cialis — avanafil is genuinely the cleanest molecule.

This is not "avanafil is safer." All four PDE5s are safe in the cardiovascular sense (provided you're not on nitrates). It's: avanafil has the cleanest receptor profile, and that translates to the lowest rate of visual and muscular side effects.

Why your doctor doesn't prescribe it.

Three reasons, all operational.

One: it's still expensive in the U.S. Petros Pharmaceuticals (which markets Stendra in the U.S. through its Metuchen Pharmaceuticals subsidiary) prices the brand version at roughly $50-65 per pill at retail cash 2026. The first generic ANDA was approved June 2024 (Hetero Labs), but as of 2026, retail cash pricing on generic avanafil 100mg sits at roughly $7-10 per pill (per SingleCare retail snapshot, April 2026), before any insurance. That's still 2-3x what generic sildenafil costs at the same pharmacy.

Two: prescribing inertia. Sildenafil came off-patent in 2017 (U.S.) and the entire pharmacy infrastructure — every pharmacy benefit manager, every PBM tier list, every telehealth backend — defaults to it. A doctor writing avanafil triggers a prior authorization in many plans. Writing sildenafil 100mg is one click. The system was built around sildenafil first.

Three: nobody asks for it. Hims, Roman, BlueChew — none of these telehealth platforms surface avanafil in their primary funnel. Their backend pharmacies stock sildenafil and tadalafil because that's where the volume is. If a patient doesn't ask, the consult provider doesn't bring it up. Most ED patients have heard of Viagra and Cialis. "Stendra" never made it into the cultural awareness layer the way the older two did, despite hitting the U.S. market in 2012.

None of these are pharmacological objections. The molecule is fine. It's a market-positioning failure that calcified into a prescribing default.

When avanafil > sildenafil — actual scenarios.

Avanafil is not a default first-line. Sildenafil 50mg is, and we say so in the 50mg vs 100mg starting-dose breakdown. Switch to avanafil only if one of the following is true:

• Sildenafil gives you a blue or hazy tinge in your vision. Not common but specific. PDE6 cross-reactivity is the cause. Avanafil drops it to near-zero.
• Tadalafil daily 5mg gives you next-day back or muscle ache. PDE11 cross-reactivity. Avanafil doesn't touch PDE11 in any clinically relevant way.
• You hate the 30-60 minute pre-loading window. You want to take a pill closer to the moment, not an hour out. The 15-minute onset isn't a marketing number; it's the genuine front-edge of the molecule's effect.
• You're over 50 and notice visual issues on sildenafil. Older men report a higher rate of mild chromatopsia. Avanafil is the cleanest swap.

If none of these apply, sildenafil 50mg costs less, works fine, and has 25 years of post-market safety data. Stay there. Avanafil is the second move, not the first.

For half-life logic across all four PDE5s, see the 4-options breakdown.

What it costs through different lanes.

Three pricing lanes, all real, all priced to different markets.

That last row is real. We carry avanafil 100mg and 200mg in 4-pack and 10-pack formats. The per-pill economics are similar to what we charge for generic sildenafil — slightly higher, because the molecule's supply chain is younger and the manufacturing footprint is smaller.

Telehealth doesn't carry avanafil because their economic model is built on auto-refills of one molecule at high margin. Stocking a third molecule with lower volume hurts their economics. The personal-import lane, which is where we operate, doesn't have that constraint — we stock what works, including the molecule the U.S. system functionally forgot.

What to do.

If sildenafil works without side effects, stay there. Avanafil is not a sidegrade for sildenafil-responders.

If sildenafil gives you blue-tinged vision, halos, or you've had recent eye surgery — avanafil is the swap.

If tadalafil daily gives you back pain or muscle aches — avanafil is the swap.

If you specifically want a 15-minute onset because you don't plan sex an hour ahead — avanafil is the answer, and there's no other molecule in the class with this onset.

Start at avanafil 100mg, taken 15-30 minutes before, on a light meal (heavy fat delays absorption ~30 minutes — same as sildenafil). If 100mg is too much (rare — most men handle it), 50mg is splittable. If 100mg isn't enough, 200mg is available, but escalation past 100mg has diminishing returns above moderate ED.

LiberaCure carries avanafil 100mg and 200mg in 4-pack starters at the price band above. If sildenafil's been your default and it's not quite right, the 4-pack is the cheapest way to find out whether your problem is the molecule or the dose.

For the full ED framework — when to swap molecules, when to stack with daily tadalafil, when the issue isn't the pill at all — see the comprehensive guide.

A note on bias.

We route avanafil orders. Be aware of that.

LiberaCure routes orders to licensed personal-import pharmacies. Our avanafil line sources through ED-specialist firms (Sunrise Remedies' Avanair is one of them) — because the global pharma giants (Cipla, Sun Pharma, Dr. Reddy's) don't currently make avanafil at scale. The molecule is newer, the margin tighter, and the giants haven't built the line yet. So we have a financial reason to want this article to lead you toward "give it a try."

Read this with that in mind. The protocol above — stay on sildenafil if it works, only switch for specific reasons — is what I'd tell a friend, not what maximizes reorder rate.

Sources:

• Goldstein I et al. A randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of avanafil in subjects with erectile dysfunction. J Sex Med 2012;9(4):1122-1133. PMID 22248153
• Wang R et al. Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability. J Sex Med 2012;9(8):2122-2129.
• Mehrotra N et al. The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy. Eur Urol Suppl 2012.
• FDA Stendra label, NDA 202-276 (2012, current revision); FDA Viagra prescribing information.
• Belkoff LH, McCullough A, Goldstein I, Hellstrom WJ et al. An open-label, long-term evaluation of the safety, efficacy and tolerability of avanafil in male patients with mild to severe erectile dysfunction. Int J Clin Pract 2013;67(4):333-341. PMID 23521325
• SingleCare retail pricing snapshot, generic avanafil 100mg, April 2026.
• FDA Orange Book — first generic avanafil ANDA approval, Hetero Labs, June 2024.

— LiberaCure editorial. We route generic medication through licensed personal-import pharmacies. We don't dispense, prescribe, or warehouse. Read more about why.